Actinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Actimab-A
May 24, 2017 09:22 ET
|
Actinium Pharmaceuticals
- Orphan designation provides increased communication and guidance from regulators and 10-year market exclusivity upon marketing authorization- Actinium’s two leading drug candidates, Iomab-B and...
Actinium Pharmaceuticals to Present Actimab-A Data at the 10th International Symposium on Targeted Alpha Therapy
May 23, 2017 07:30 ET
|
Actinium Pharmaceuticals
- Data from the Company’s Actimab-A program to be presented in the Clinical Experiences session being held on Wednesday, May 31, 2017 - Actinium is a sponsor of the conference...
Actinium Pharmaceuticals Announces Appointment of Hematology Expert Dr. Richard Stone of the Dana-Farber Cancer Institute to its Scientific Advisory Board
May 17, 2017 07:00 ET
|
Actinium Pharmaceuticals
Dr. Stone is a world renowned physician with extensive research and clinical experience focused on refractory leukemia patients and advanced myeloproliferative disordersActinium’s Scientific Advisory...
Actinium Pharmaceuticals Receives Clearance from Health Canada to Initiate Pivotal Phase 3 SIERRA Trial of Iomab-B
May 10, 2017 07:00 ET
|
Actinium Pharmaceuticals
NEW YORK, May 10, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload...
AXIM® Biotech Expands Advisory Board With Oncology Specialist and Medicinal Cannabis Leading Expert – Dr. Donald Abrams
May 09, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced the addition to its...
Preclinical Data on Aptose Biosciences FLT3/BTK Inhibitor CG’806 Presented at AACR Hematologic Malignancies Meeting
May 08, 2017 08:00 ET
|
Aptose Biosciences Inc.
SAN DIEGO and TORONTO, May 08, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced the presentation of preclinical data demonstrating that CG’806, a highly...
OHSU and Aptose Present CG’806 Preclinical Data Demonstrating Potent Activity Against Patient Samples at AACR Hematologic Malignancies Meeting
May 08, 2017 08:00 ET
|
Aptose Biosciences Inc.
PORTLAND, Ore., SAN DIEGO, and TORONTO, May 08, 2017 (GLOBE NEWSWIRE) -- Oregon Health & Science University (OHSU) and Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) announced the...
Actinium Pharmaceuticals Announces Sponsorship of the Acute Leukemia Forum 2017
April 18, 2017 07:00 ET
|
Actinium Pharmaceuticals
- Event to bring together worldwide experts to share and discuss latest research that is influencing treatment and management of patients with acute leukemia - Members of Actinium’s...
Actinium Pharmaceuticals Appoints Pharmaceutical Industry Executive Ajit S. Shetty, Ph.D., to the Company’s Board of Directors
March 28, 2017 07:00 ET
|
Actinium Pharmaceuticals
- Proven leader with 36 years of experience with Johnson & Johnson in numerous executive capacities, most recently as Head of Enterprise Supply Chain- Dr. Shetty was instrumental in establishing...
Actinium Announces Receipt of Positive Scientific Advice from the European Medicines Agency for Iomab-B
March 21, 2017 07:00 ET
|
Actinium Pharmaceuticals
- EMA guidance provides clear regulatory pathway for EU approval for Iomab-B - Trial design, primary endpoint and planned statistical analysis from the Iomab-B U.S. pivotal Phase 3 SIERRA trial...